Современные подходы к лечению сахарного диабета 2-го типа и его осложнений

По данным Международной диабетической федерации, сахарным диабетом (СД) в мире болеют более 366 млн человек, а к 2030 г. число больных увеличится до 552 млн. Актуально лечение пациентов препаратами, с одной стороны, воздействующими на различные звенья патогенеза СД, а с другой - оказывающими профилактическое действие. При среднем значении уровня HbA1c 7-8% лечение диабетоном МВ снижает этот показатель на 0,9%; при уровне HbA1c 8-9% - на 1,7%, при его уровне 8-9% - на 2,6%, а при значениях свыше 10% - на 4,2%. Помимо сахарснижающей активности, диабетону МВ присущи независимые эффекты: снижение интенсивности окисления ЛПНП, адгезии и агрегации тромбоцитов, адгезии моноцитов и т.д.

сахарный диабет, инсулинотерапия, НПХ, инсулин гларгин

1. Butler P.C., Meier J.J., Butler A.E., Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758-768.

2. Аметов А.С. Нарушения жизненного цикла и функции Β-клеток поджелудочной железы: центральное звено патогенеза cахарного диабета 2-го типа. Учебное пособие. М 2002.

3. Barr R.G., Nathan D.M., Meigs J.B., Singer D.E. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Int Med 2002; 137: 4: 263-272.

4. UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.

5. Riddle M. et al. Сhallenging the "Monnier concept": High basal (not postpandial) glucose dominates hyperglycaemic exposure over a wide range of HbA1c in oral therapy and contributes significantly even after addition of basal insulin. Diabetologia 2010; 53: Suppl 1: Abstart 999.

6. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. 5-е изд. М 2011.et al.

7. Gaede P.S. et al. Effect of multifactorial intervention оn mortality in Type 2 diabetes. N Engl J Med 2008; 258: 580-591.

8. Ramlo-Halsted B.A., Edelman S.V. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care 1999; 26: 4: 771-789.

9. De Fronzo R.A. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50: 5: 191-197.

10. Gerstein H.C., Yale J.-F., Harris S.B., Issa M., Stewart J.A., Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-742.

11. Blicklé J.F., Hancu N., Piletic M., Profozic V., Shestakova M., Dain M.P., Jacqueminet S., Grimaldi A. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009; 11: 4: 379-386.

12. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.

13. Chang-Yu Pan et al. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabet Res Clin Pract 2007; 76: 111-118.

14. Riddle M.C. et al. The Treat-to-Target Trial. Diabetes Care 2003; 26: 3080-3086.

15. Rosenstock J., Schwarts S.L., Clark C.M.Jr., Park G.D., Donley D.W., Edwards M.B. Diabetes Care 2001; 24: 631-636.

16. Yki-Jarvinen H., Dressler A., Ziemen M. HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 8: 1130-1136.

17. Davies M., Evans R., Storms F. et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes. Comparison of two treatment algorithms using insulin glargine . Diabetes Care 2005; 28: 1282-1288.

18. Ярек-Мартынова И.Р., Шамхалова М.Ш., Шестакова М.В. Эффективная фармакотерапия в эндокринологии. М 2010; 6: 24-28.

19. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., Vaha­talo M., Virtamo H., Nikkila К., Tulokas T., Hulme S., Hardy К.,McNulty S., Hanninen J., Levanen H., Lahdenpera S., Lehtonen R., Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 3: 442-451.

20. Schreiber S.A., Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on.oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9: 1: 31-38.

21. Schreiber S.A., Ferlinz K., Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008; 10: 2: 121-127.

22. The ORIGIN Trial Investigators Hamilton, Ontario, Canada. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155: 26-32: e6.

23. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. The New England Journal of Medicine. 2012, NEJM.org

24. Nathan D.M., Busse J.B., Davidson M.B. Medical management of hyperglycemia in type 2 diabetes: aa consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabet Care 2009; 32: 193-203.